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Solar  UVB  is carcinogenic.  Nucleotide  excision  repair  (NER)  counteracts  the  carcinogenicity  of  UVB  by
excising  potentially  mutagenic  UVB-induced  DNA  lesions.  Despite  this  capacity  for DNA  repair,  non-
melanoma  skin  cancers  and  apparently  normal  sun-exposed  skin  contain  huge  numbers  of  mutations
that  are mostly  attributable  to unrepaired  UVB-induced  DNA lesions.  UVA  is about  20-times  more  abun-
dant  than  UVB  in incident  sunlight.  It  does  cause  some  DNA  damage  but  this  does  not  fully  account
for  its biological  impact.  The  effects  of  solar  UVA  are  mediated  by its interactions  with  cellular  photo-ucleotide excision repair
kin cancer
utation
sensitizers  that  generate  reactive  oxygen  species  (ROS)  and  induce  oxidative  stress.  The proteome  is  a
signiﬁcant  target  for damage  by UVA-induced  ROS.  In cultured  human  cells,  UVA-induced  oxidation  of
DNA  repair  proteins  inhibits  DNA  repair.  This  article  addresses  the  possible  role  of oxidative  stress  and
protein  oxidation  in  determining  DNA  repair  efﬁciency  – with  particular  reference  to  NER  and skin cancer
risk.
© 2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction
.1. UV and DNA damage
Although exposure to sunlight ultraviolet (UV) radiation is ben-
action spectra (reviewed in [2]) identiﬁed 265 nm in the UVC region
as the most biologically effective wavelength in microorganisms
and identiﬁed DNA as the principal damage target. As a conse-
quence, most research into the biological effects of UV has been
based on germicidal mercury lamps emitting predominantly UVCﬁcial and enhances vitamin D levels [1], it also causes cancer. The
olar UV radiation spectrum (wavelengths 100–400 nm)  comprises
VC (<280 nm), UVB (280–320 nm)  and UVA (320–400 nm). Early
Abbreviations: NER, nucleotide excision repair; ROS, reactive oxygen species;
V,  ultraviolet; CPD, cyclobutane pyrimidine dimer; 6:4Py:Py, 6:4 pyrimi-
ine:pyrimidone; 1O2, singlet oxygen; 6-TG, 6-thioguanine.
∗ Corresponding author.
E-mail address: peter.karran@crick.ac.uk (P. Karran).
ttp://dx.doi.org/10.1016/j.dnarep.2016.05.024
568-7864/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uradiation. Germicidal UV produces DNA cyclobutane pyrimidine
dimers (CPDs) and pyrimidine:pyrimidone 6:4 photoproducts (6:4
Py:Pys) as predominant photolesions. The involvement of these
bipyrimidine photoproducts in UV-induced mutagenesis is well
established and many of the processes that underlie the biological
effects of shorter wavelength UV are well understood. Their pro-
cessing by DNA repair/tolerance pathways and the DNA damage
responses that they elicit in both simple and more complex organ-
isms are known in some detail [3]. Importantly, these studies have
also established the essentially conserved nature of the nucleotide
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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xcision repair (NER) system that protects against cell death and
utation by removing CPDs and 6:4 Py:Pys. If unrepaired, the DNA
esions induced by short wavelength UV induce characteristic C > T
ransition mutations at dipyrimidine sites. These mutations are
egarded as the signatures of UV exposure. Of particular relevance
o this review, the seminal observations that NER is defective in
broblasts from sun-sensitive and skin cancer-prone xeroderma
igmentosum (XP) individuals deﬁned the relationship between
nrepaired UV-induced DNA damage and skin cancer susceptibility
4,5]. These were crucial in establishing the paradigm of an inverse
elationship between DNA repair proﬁciency and cancer risk.
The stratospheric ozone layer ﬁlters solar emissions and the
unlight UV radiation to which we are exposed comprises approx-
mately 5% UVB and 95% UVA. It does not contain UVC. Germicidal
V is nevertheless a reasonable surrogate for some of the effects
f sunlight on skin, including mutagenesis and carcinogenesis,
ecause CPDs and 6:4 Py:Pys are also the predominant photoprod-
cts of the shorter wavelengths of solar UVB. At longer wavelengths,
he contribution of the canonical UV DNA photoproducts to cel-
ular damage declines sharply. Biologically relevant UVA doses
nduce several orders of magnitude fewer CPDs (and effectively
o 6:4 Py:Pys) [6]. Unlike UVC and UVB, UVA interacts with cellu-
ar photosensitizers to generate reactive oxygen species (ROS) and
OS-mediated oxidative damage to DNA and to non-DNA targets
ecomes increasingly signiﬁcant. Overall, however, UVA induces
ittle DNA damage [7]. Because of this and because mutation anal-
ses clearly identify the canonical UVB photoproducts as the main
utation-inducing DNA lesions in skin cancer development, the
otential contribution of UVA to cancer risk has received less atten-
ion. This review examines the evidence that the UVA in incident
unlight inﬂuences mutation and skin cancer risk and that it does
his independently of its ability to damage DNA.
.2. DNA damage and the cellular effects of UVA
CPDs and 6:4 Py:Pys are generated in oxygen-independent reac-
ions whereas many of the biological effects of the longer UVA
avelengths are dependent on oxygen [8]. Although UVA does
ause oxidative DNA damage, extensive analysis of DNA from UVA-
rradiated cells indicates that oxidative DNA lesions are likely
o contribute little to its toxicity and mutagenicity. Surprisingly,
PDs (predominantly T <> T) are quantitatively the major UVA
hotoproduct and the contribution from oxidative DNA lesions is
onsiderably more modest [7]. This is consistent with the rela-
ive infrequency of the signature mutation of the most common
xidized DNA base – the G > T transversions associated with DNA
-oxoGuanine – in most UVA mutation spectra [9]. Rather, these
re dominated by signature dipyrimidine C > T mutations.
The canonical UV photoproducts appear not to be signiﬁcant
ontributors to the biological effects of UVA. NER-defective XP cells
hat are extremely sensitive to UVC and UVB are not hypersensi-
ive to UVA [10]. Moreover, although the effects of UVC and UVB in
xcision-proﬁcient cells correlate well with the induction of canon-
cal UV lesions, this type of damage cannot fully explain the toxicity
nd mutagenicity of UVA. Thus, a CPD induced by UVC or UVB is
ssociated with 5–10 times less toxicity and mutagenicity than the
ame lesion induced by UVA [11,12]. Additionally, CPDs induced by
VA in NER-proﬁcient cells persist for longer than the same lesions
nduced by UVC or UVB [13,14], suggesting that their repair might
e compromised at longer wavelengths.Taken together, the response of cells to UVA radiation and thor-
ugh analyses of UVA-damaged DNA suggest that damage to targets
ther than DNA is likely to be a signiﬁcant contributor to the bio-
ogical effects of UVA.air 44 (2016) 178–185 179
1.3. DNA damage by UVA photosensitizers
The oxygen dependence of the effects of UVA reﬂects the activa-
tion of endogenous photosensitizers to generate ROS. These cellular
photosensitizers have not been fully characterized but candidates
include porphyrins, ﬂavins [15] and melanin [16]. Their properties
can, however, be mimicked to a certain degree by photosensitizing
drugs such as the thiopurines and the ﬂuoroquinolone antibiotics.
Photosensitizing drugs are linked to an increased skin cancer risk
[17,18]. Because they amplify the effects of endogenous photo-
sensitizers and the consequences of their interactions with UVA
can be examined under laboratory conditions, these therapeutic
photosensitizers offer an important approach to understanding the
events associated with UVA photosensitization.
The thiopurine prodrug azathioprine (Fig. 1) provides a dra-
matic example of an increased skin cancer risk associated with UVA
exposure. An immunosuppressant that has been widely prescribed
to prevent rejection in organ transplant patients, azathioprine is
also used in the management of inﬂammatory bowel conditions.
In both treatment contexts, azathioprine is associated with a sig-
niﬁcantly increased risk of non-melanoma skin cancer, principally
squamous cell carcinomas (SCC) that appear almost exclusively
on sunlight-exposed parts of the body. The frequency of SCC in
organ transplant recipients is around 100-fold higher than nor-
mal  [19] and there is a more modest but still signiﬁcant increase
in patients treated for inﬂammatory bowel disorders [20,21]. Aza-
thioprine treatment is associated with skin photosensitivity to UVA
(but not UVB) [22]. Population studies of French and British organ
transplant patients implicate solar UVA in their increased skin can-
cer risk. Facial tumors in French patients arise predominantly on the
left side, those in British patients on the right side of the face. This
is consistent with the involvement of UVA from glass-ﬁltered UV
(UVB does not penetrate glass whereas UVA does) during driving
[23].
The azathioprine metabolite 6-thioguanine (6-TG) replaces a
small fraction of the patients’ DNA guanine [24]. 6-TG is a strong
UVA chromophore and its presence in patients’ DNA is consis-
tent with their selective UVA photosensitivity [22]. In cultured
cells, DNA 6-TG acts as both a Type I and a Type II UVA pho-
tosensitizer and interacts with UVA to generate ROS, principally
singlet oxygen (1O2) in a Type II photosensitized reaction. These
ROS cause widespread DNA damage including oxidized bases [22],
DNA breaks [25], DNA interstrand crosslinks [26], and DNA-protein
crosslinks [27]. Importantly, the DNA 6-TG/UVA combination also
causes widespread protein oxidation [28].
The expectation that a contribution of azathioprine/UVA-
induced DNA lesions to skin cancer development would be evident
from novel signature mutations in transplant-related skin tumors
was not fulﬁlled. The mutational spectra of the frequently mutated
PTCH [29] and TP53 genes [30] from skin tumors of immuno-
suppressed patients were found to be closely similar to those of
immunocompetent individuals and were dominated by the char-
acteristic dipyrimidine C > T mutations of canonical UV DNA lesions.
These observations ﬁrmly identiﬁed UVB as the mutagen. The
absence of new signature mutations in tumors from immunosup-
pressed individuals suggested that rather than inﬂuencing cancer
risk by inducing novel mutagenic DNA lesions, the combination
of sun exposure and azathioprine enhances the mutagenicity of
solar UVB, potentially through damage to non-DNA targets such as
proteins.
Clinical photosensitivity similar to that caused by azathioprine
is a common side effect of drug treatment and is often associated
with an increased skin cancer risk [17,18]. The ﬂuoroquinolone
antibiotics are recognised clinical photosensitizers that are also
UVA sensitizers in cultured cells [31]. Examples include the widely-
prescribed ciproﬂoxacin, oﬂoxacin and lomeﬂoxacin (Fig. 1). Unlike
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Fig. 1. UVA
-TG, ﬂuoroquinolones are not incorporated into DNA but they
evertheless replicate many of the photochemical effects of 6-TG.
hey are all Type II UVA photosensitizers [31] that exhibit a syn-
rgistic lethality and mutagenicity [32,33] with UVA in cultured
ells. Some, but not all ﬂuoroquinolone/UVA combinations induce
 <> T (but not other) CPDs by a triplet energy transfer mechanism
34]. Because they are a source of ROS, they all generate oxidative
NA lesions and also damage other cellular components, including
roteins [33].
Riboﬂavin (Fig. 1) is another recognised UVA photosensitizer
hat generates ROS and oxidative DNA damage. Although mutations
nduced by riboﬂavin/UVA in treated cultured cells are consistent
ith unrepaired oxidative DNA lesions [35], some of the effects of
his combination occur independently of DNA damage. Thus, DNA
eplication arrest induced by riboﬂavin/UVA is independent of the
anonical ATR-, ATM or p38-dependent cell cycle checkpoints that
re triggered by the presence of DNA lesions [36]. Like azathio-
rine and the ﬂuoroquinolones, ROS generated by the interaction
etween UVA and riboﬂavin cause widespread damage to proteins
37].
6-formylindolo[3′2-b]carbazole (FICZ) is a naturally-occurring
VA chromophore. FICZ (Fig. 1), a UVB photoproduct of tryptophan,
s synergistically lethal with UVA [38]. UVA activation of nanomolar
oncentrations of FICZ generates ROS, including 1O2 that causes
xidative damage to both DNA [38] and proteins (RB, unpublished).
The unifying feature of these photosensitizers is that their acti-
ation by UVA generates ROS that causes both DNA and protein
amage.
.4. Protein damage & DNA repairSome highly resistant organisms withstand huge doses of radi-
tion that cause massive DNA damage. The bacterium Deinococcus
adiodurans can reconstitute functional chromosomes from tinyFICZ
sensitizers.
DNA fragments – a feat of DNA repair beyond the capability of more
normally radiation-sensitive bacteria (reviewed in [39]). The aston-
ishing DNA repair capacity of D. radiodurans is shared by related
bacteria and certain highly radiation-resistant microscopic aquatic
rotifers [40] and tadigrades [41]. It reﬂects particularly efﬁcient
antioxidant defences that allow these organisms to withstand the
severe oxidative stress that accompanies desiccation. In particular,
a multitude of very efﬁcient antioxidant systems prevent protein
oxidation and protect essential survival systems, including DNA
repair [42]. The radiation resistance of these organisms highlights
the susceptibility of the proteome to inactivation by oxidation and
emphasizes the need to protect DNA repair proteins from damage
in order to preserve genome stability.
Oxidative stress, an unwanted excess of ROS  is also a threat to
the viability of human cells and they invest considerable resources
in anti-oxidant defences. Despite this protection, the human pro-
teome is vulnerable to damage and inactivation by ROS  if redox
homeostasis is perturbed. As a source of ROS via its interaction
with cellular chromophores, UVA radiation causes extensive pro-
tein modiﬁcation [43]. In principle, all amino acid side chains can be
oxidized to generate protein carbonyl groups. The sulphur groups
of methionine and cysteine are also particularly susceptible to
oxidation. Several DNA replication/repair proteins, including the
PCNA DNA clamp and the MCM2  replication initiation factor have
been shown to be targets for damage by UVA. UVA  in combination
with exogenous photosensitizers causes extensive ROS-dependent
intersubunit crosslinking of the PCNA, Ku and RPA DNA repair com-
plexes [33,44,45].
1.5. UVB/UVA interactionsThere are indications that UVA can enhance the effects of UVB on
skin. Photoaugmentation – the intensifying effect of wavelengths
>320 nm on erythema induction by simulated solar radiation (SSR)
P. Karran, R. Brem / DNA Rep
Table  1
DNA repair proteins known to be oxidation targets.
Protein Reference
PCNA Montaner et al. [44]
Ku Gueranger et al. [28]
RPA Guven et al. [45]; Wang et al. [82]
XRCC3 Girard et al. [83]
OGG-1 Bravard et al. [84]; Morreall et al. [85]
PARP-1 Ding et al. [86]
XPA Grosskopf et al. [87]; Zhou et al. [88]
TFIIH(p44) Fribourg et al. [89]
XPE Grosskopf et al. [87]
APE1 Kelley et al. [90]
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cinomas is partly a reﬂection of their relatively low NER efﬁciency
[59]. It is noteworthy that oxidative stress generally enhances sus-
ceptibility to drugs that kill by damaging DNA. BSO treatmentas described almost 50 years ago [46]. Erythema is the skin red-
ess associated with sunburn and is generally considered to reﬂect
amage to and death of keratinocytes. Although subsequent inves-
igations questioned whether these effects on erythema were truly
ore than additive [47], more recent studies provide support for
ynergy between UVA and UVB. In particular, UVA has been shown
o enhance UVB-induced suppression of immune responses such as
ontact hypersensitivity to nickel [48]. Interactions between UVB
nd UVA are also apparent at the cellular level and non-toxic doses
f UVA sensitize bacteria and cultured human cells to killing by UVB
49,50]. Direct evidence that UVA can inﬂuence DNA repair was pro-
ided by the observation that UVA (365 nm)  inhibits the removal
y NER of UVC- (254 nm)  induced photoproducts in Escherichia coli
49]. There is longstanding indirect evidence that UVA may  also
ompromise NER in human cells. Thus, irradiation at 365 nm causes
 dose-dependent reduction in UVC-induced unscheduled DNA
ynthesis (UDS, a measure of a late NER step) [51,52]. A UVA/UVB
ixture was found to be not only less effective than UVC in stim-
lating UDS but to actually inhibit UDS induction by both UVC and
VB [53]. Although these observations do not exclude other inter-
retations, they are nevertheless consistent with attenuation of
ER by UVA.
More recent experiments provide direct evidence that UVA can
ompromise DNA repair in human cells and that it does this by
amaging DNA repair proteins. UVA combined with 6-TG [28]
r a ﬂuoroquinolone photosensitizer [33] inhibits DNA repair in
ultured human cells. In both cases, inhibition is the result of
rotein oxidation. Oxidative damage to the Ku complex impairs
on-Homologous DNA End Joining (NHEJ) [28]. The base excision
epair of DNA 8-oxoG is also affected as both the OGG-1 and MUTYH
NA glycosylases that cooperate in the repair DNA 8-oxoGuanine
re partially inactivated [28]. Of particular signiﬁcance, oxidation of
PA compromises NER and the removal of UVC or UVB-generated
-4 Py:Pys is impaired in cells treated with a photosensitizer and
VA [45]. These and other examples of oxidation-susceptible DNA
epair proteins are listed in Table 1.
The extensive protein damage induced by photosensitized UVA
28,33] has even found a therapeutic application. Collagen ﬁbers
re deliberately targeted for crosslinking by riboﬂavin/UVA in the
reatment of keratoconus, a condition that weakens the cornea [54].
Importantly, these photosensitizers simply exacerbate the
ffects of UVA and at higher doses, UVA alone induces sufﬁcient
rotein oxidation to inhibit DNA repair [55]. The formation of ROS is
he key factor in DNA repair inhibition by UVA and exogenous pho-
osensitizers that are weak sources of ROS such as the halogenated
hiopyrimidines, do not signiﬁcantly inhibit repair [56,57].
These ﬁndings emphasize the vulnerability of human DNA
epair to inhibition by protein damage by ROS induced by UVA
ither alone or in combination with an exogenous photosensitizer.air 44 (2016) 178–185 181
1.6. Oxidative stress compromises NER
If ROS induced by UVA cause protein damage that inhibits
DNA repair, it is appropriate to ask whether NER is vulnerable to
other interventions that induce oxidative stress. The excess ROS
that deﬁne oxidative stress results from an imbalance between
their formation and removal. This can be induced experimentally
by compromising cellular antioxidant defences. Treatment with
the glutamylcysteine synthetase inhibitor buthionine sulfoximine
(BSO) depletes cells of the important antioxidant glutathione (GSH).
The oxidative stress associated with GSH depletion results in an
increased steady-state level of protein oxidation and BSO treatment
enhances UVA-induced protein oxidation in human keratinocytes.
The increased levels of protein oxidation are associated with an
inhibition of NER and cells treated with UVA and BSO do not excise
UVB-induced photoproducts [55]. The observed NER inhibition
provides an explanation for the reversal of resistance to the anti-
cancer drug cisplatin that follows BSO treatment [58]. By removing
potentially toxic cisplatin-DNA lesions, NER is an acknowledged
contributor to cisplatin resistance [59] and its inhibition would be
consistent with increased cisplatin sensitivity.
Pharmacologically active, high concentrations of ascorbate
(vitamin C) sensitize cells to carboplatin, a cisplatin analog. At
these high concentrations, ascorbate acts in a pro-oxidant fashion
to induce oxidative stress. It generates H2O2 and causes oxidative
DNA damage [60]. H2O2 itself is widely used to induce oxidative
stress. Although rather unreactive, it is converted into the much
more reactive hydroxyl radical (OH•) by the Fenton reaction. In
addition to DNA damage, H2O2 also causes extensive protein oxi-
dation and treatment of cultured human HaCaT keratinocytes with
either H2O2 or high concentrations of ascorbate inhibits NER [55].
Cells adapt to oxidative stress by diverting glucose metabolism
from glycolysis to the pentose phosphate pathway (PPP). One out-
come of this metabolic switch is a boost in the production of
the NADPH that is required to maintain antioxidant defences by
recycling oxidized GSH. By preserving reducing power, increased
ﬂux through the PPP protects against both DNA and protein oxi-
dation. Silencing of glucose-6-phosphate dehydrogenase (G6PD),
the ﬁrst and rate-limiting step of the PPP, prevents this metabolic
switch. G6PD silencing is associated with decreased NADPH levels,
increased protein oxidation and inhibition of NER [55] . In a related
outcome, compromised G6PD activity is associated with oxidative
damage to the Ku protein complex, inhibition of DNA break repair
by the Non-Homologous End Joining pathway and enhanced ioniz-
ing radiation sensitivity [61–63].
The TCA cycle also supplies NADPH, in this case via the oxida-
tive decarboxylation of isocitrate to -ketoglutarate by isocitrate
dehydrogenase (IDH). Heterozygous mutations in the IDH1 isoform
are particularly common in gliomas, chondrosarcomas and some
leukemias. Gain of function IDH1 mutations confer the ability to
reduce -ketoglutarate to -hydroxyglutarate in a reaction that
consumes NADPH [64]. Mutant IDH1 is associated with decreased
NADPH levels, a better prognosis and superior response to therapy.
It is possible that diminished DNA repair contributes to this pheno-
type. In support of this possibility, restoration of high NADPH levels
by inhibiting the mutant IDH1 isoform in HT1080 chondrosarcoma
cells protects them against UVA-mediated NER inhibition [55].
The therapeutic effectiveness of many anticancer agents is com-
promised by the removal of potentially lethal DNA lesions by NER
and they are more effective against tumors in which NER is compro-
mised. This is particularly evident with the platinum-based drugs
and the spectacular success of cisplatin in treating testicular car-reverses the cisplatin resistance of glioma cells in culture and in
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Fig. 2. Mutation burden in human tumors.
The median values for mutation frequencies in human tumors. Data are taken from refs. [91] and [92]. MSS  microsatellite stable, MSI  microsatellite unstable. Frequencies
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cor  melanoma also include those from refs. [93], [94] and [95] (desmoplastic). Bas
nclude  those of refs. [97] and [98]. Normal skin values from ref. [71]. PDE is colore
ata  are from ref. [99]. Where more than one study has been reported, approximate
enografts [65]. Very high doses of ascorbate sensitize ovarian car-
inoma cells to carboplatin [60]. G6PD overexpression is associated
ith cisplatin resistance [66] and G6PD silencing confers cisplatin
ensitivity in cultured human cells [55]. IDH1 mutations also con-
er sensitivity to a number of therapeutic drugs including cisplatin
67,68] and overexpression of wild-type IDH1 in cultured cells pro-
ects against UVB-induced apoptosis [69]. All of these observations
re consistent with an association between oxidative stress and
ttenuated NER and a likely molecular mechanism for this NER
nhibition is via increased protein oxidation.
In summary, DNA repair proteins are susceptible to damage
nd inactivation by oxidation. Interventions that are known to
nduce oxidative stress damage DNA repair proteins and inhibit
NA repair. UVA inhibits NER [55] and its effects are ampliﬁed
y exogenous photosensitizers that increase oxidative stress. Since
VA comprises around 95% of incident solar UV and is a source
f ROS via its interaction with cellular photosensitizers, it seems
ertinent to question the extent to which solar UVA affects the
ER of UVB-induced DNA lesions in skin. How efﬁcient is NER
n sun-exposed skin? How good is the protection NER provides
gainst mutation by solar UVB? DNA sequencing data from skin
umors suggests that the effectiveness of NER might be less than
ptimal.
.7. UVA and skin cancer mutations
A remarkable characteristic of tumors from sun-exposed skin
s their high number of mutations. The mutational loads in BCCs
nd SCCs are more than an order of magnitude higher than those
n tumors of other anatomical sites (Fig. 2). Even morphologi-
ally normal skin [70,71] has accumulated more mutations than
any non-skin tumors. Skin carcinoma mutation frequencies are
omparable to those in colorectal tumors with a mismatch repair
eﬁciency (Lynch Syndrome) or defective replication proofreading
72] both of which confer extremely high spontaneous mutation
ates. There are, however, no known DNA repair or replication
rror-correcting defects in skin tumors and mutations in NER genes
re infrequent in skin cancer. Despite protection by NER, the over-
helming majority of mutations in skin tumors and normal skin
ear the signature of solar UVB.These huge mutational loads might simply reﬂect chronic sun
xposure and the extremely powerful mutagenicity of UVB. In a
ifferent context, however, UVB is not a particularly potent car-
inogen. UVB phototherapy is an effective treatment option for the skin carcinoma numbers are from ref. [96]. Squamous cell carcinoma frequencies
arcinomas with DNA polymerase ∂/ proofreading mutations. Mutation frequency
n values are presented. Skin and skin tumors are shown in red.
management of chronic relapsing skin conditions such as psori-
asis. It involves repeated (up to several hundred) and escalating
doses of narrowband UVB that produce levels of DNA damage
roughly equivalent to those induced by two minimal erythema
doses (MEDs) of solar radiation [73,74]. MED  is the dose of radi-
ation that causes just perceptible erythema on skin not normally
exposed to the sun. For comparison, this means that CPD induc-
tion by each UVB treatment is approximately equivalent to 0.2 J/m2
UVC delivered to cultured cells. Despite this extensive UVB expo-
sure, UVB phototherapy is not associated with a detectable cancer
risk [75,76]. In contrast, management of the same skin conditions
by multiple treatments with psoralen/UVA (PUVA) which causes a
different kind of DNA damage, carries a well-established and sig-
niﬁcant cancer risk [75]. The absence of detectable carcinogenicity
associated with therapeutic UVB suggests that it might be less of
a hazard than solar UV. We  suggest that sunlight UVA contributes
to this differential carcinogenicity and that by decreasing the efﬁ-
ciency of NER, UVA increases the mutagenicity of coincident UVB.
Skin cancer is common and available mutation data clearly
implicate UVB photoproducts in its development. NER does pro-
tect against skin cancer and the extreme skin cancer susceptibility
of NER-defective XP individuals testiﬁes to the carcinogenicity of
unrepaired UV-induced DNA damage. The topical application of
liposomally-encapsulated DNA repair enzymes [77,78] that ame-
liorates many of the effects of UV-induced DNA damage in the
skin of XP patients [79], also protects repair-competent individuals
[77,78]. This indicates that the efﬁciency of photoproduct removal
can be improved over that provided by basal NER. Estimates of the
rates of photoproduct excision from the skin of UV-irradiated vol-
unteers provide some support for this possibility. Although these
vary widely and there is signiﬁcant inter-individual variation that
may  be partly dependent on skin type (for example: [74,80,81])
these studies suggest that damage excision rates are generally con-
siderably lower in intact skin than those we normally measure in
laboratory experiments with cultured cells exposed to UVC. A sig-
niﬁcant fraction (>60%) of CPDs induced in skin by solar UV may
persist for two  or more days after irradiation.
Most of us are and will remain unaffected by skin cancer. If
oxidative protein damage by solar UVA does compromise NER and
contribute to mutation and skin cancer risk, its effect is likely to be
subtle and cumulative. In practical terms, the possibility that the
long and short wavelengths of solar UV interact synergistically in
cancer development dictates that truly effective skin cancer pre-
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ention requires protection against the whole solar spectrum with
fﬁcient screening of both UVA and UVB radiation.
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